Globus Medical Reports First Quarter 2021 Results

Go back to Globus Medical Reports First Quarter 2021 Results

Globus Medical (GMED) PT Raised to $73 at Stifel

May 5, 2021 9:36 AM EDT

Stifel analyst Mathew Blackman raised the price target on Globus Medical (NYSE: GMED) to $73.00 (from $60.00) while maintaining a Hold rating.

The analyst commented, "We expected GMED to post a strong 1Q, but the company's near-20% growth -- despite meaningful, early 1Q COVID... More

Globus Medical (GMED) Tops Q1 EPS by 12c, Offers Guidance

May 4, 2021 4:43 PM EDT

Globus Medical (NYSE: GMED) reported Q1 EPS of $0.49, $0.12 better than the analyst estimate of $0.37. Revenue for the quarter came in at $227.3 million versus the consensus estimate of $198.39 million.

GUIDANCE:

Globus Medical sees FY2021 EPS of $1.83-$1.89, versus the consensus of $1.84.... More